Guanabenz combination therapy inhibits sympathetic nerve activity and regresses left ventricular hypertrophy

Cardiovascular Drugs and Therapy

Volumn 14, Issue 1, 2000, Pages 61-66

  Miyajima, Eiji ^a,b   Shigemasa, Tomohiko ^a   Endo, Tsutomu ^a   Hishiki, Satoshi ^a   Kawano, Yoshiyuki ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

2 agonist; Essential hypertension; Heart rate variability; Muscle sympathetic nerve activity; Norepinephrine

Indexed keywords

ADRENALIN; ANTIHYPERTENSIVE AGENT; GUANABENZ;

ADRENALIN BLOOD LEVEL; ADRENERGIC ACTIVITY; ADULT; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART RATE; HUMAN; HYPERTENSION; MALE; MOBILIZATION; PRIORITY JOURNAL; REST; SYMPATHETIC NERVE; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; FEMALE; GUANABENZ; HEART RATE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; NOREPINEPHRINE; ORGAN SIZE; SYMPATHETIC NERVOUS SYSTEM; SYMPATHOLYTICS;

EID: 0034007819     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007895222149     Document Type: Article

References (38)

1. 1. Folkow B. Physiological aspects of primary hypertension. Physiol Rev 1982;62:347-504.
2. 2. Miyajima E, Yamada Y, Matsukawa T, Tochikubo O, Ishii M, Kaneko Y. Neurogenic abnormalities in young borderline hypertensives. Clin Exp Hypertens 1988;A10(Suppl.1):209-223.
3. 3. Yamada Y, Miyajima E, Tochikubo O, Matsukawa T, Ishii M. Age-related changes in muscle sympathetic nerve activity in essential hypertension. Hypertension 1989;13:870-877.
4. 4. Miyajima E, Yamada Y, Yoshida Y, et al. Muscle sympatheticnerve activity in renovascular hypertension and primary aldosteronism. Hypertension 1991;17:1057-1062.
5. 5. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. NIH publication No. 98-4080. Washington, DC: NIH, 1997.
6. 6. Wollam GL, Hall WD, Porter VD, et al. Time course of regression of left ventricular hypertrophy in treated hypertensive patients. Am J Med 1983;75:100-110.
7. 7. Casale PN, Devereux RB, Milner M, et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986;105:173-178.
8. 8. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 1990;322:1561-1566.
9. 9. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994;90:1786-1793.
10. 10. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertension 1995;13:1091-1095.
11. 11. Simpson P. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha-1 adrenergic response. J Clin Invest 1983;72:732-738.
12. 12. Pegram BL, Frohlich ED. Cardiovascular adjustment to antiadrenergic agents. Am J Med 1983;75:94-99.
13. 13. Tarazi RC. Regression of left ventricular hypertrophy by medical treatment: present status and possible implications. Am J Med 1983;75(Suppl. 3A):80-86.
14. 14. Timio M, Venanzi S, Gentili S, Ronconi M, Del Re G, Del Vita M. Reversal of left ventricular hypertrophy after one-year treatment with clonidine: relationship between echocardiographic findings, blood pressure, and urinary catecholamines. J Cardiovasc Pharmacol 1987;10(Suppl. 12):s142-s146.
15. 15. Sen S, Tarazi RC, Bumpus FM. Cardiac hypertrophy and antihypertensive therapy. Cardiovasc Res 1977;11:427-433.
16. 16. Long CS, Kariya K, Karns L, Simpson PC. Sympathetic activity: Modulator of myocardial hypertrophy. J Cardiovasc Pharmacol 1991;172:s20-s24.
17. 17. Marcus R, Krause L, Weder AB, Mejia AD, Schork NJ, Julius S. Sex-specific determinants of increased left ventricular mass in the Tecumseh blood pressure study. Circulation 1994;90:928-936.
18. 18. Tan SA, Berk LS, Tan LG. Indapamide regresses, but transdermal clonidine does not regress, left ventricular hypertrophy in hypertensive diabetic patients. Am J Cardiol 1996; 77:20B-22B.
19. 19. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. Am J Hypertens 1992;5:95-110.
20. 20. Kleine P, Meissner E, von Bruchhausen V, Bruckner S. Effects of clonidine and nifedipine on left ventricular hypertrophy and muscle mass in hypertensive patients. J Cardiovasc Pharmacol 1987;10(Suppl. 12):s180-186.
21. 21. Strauer BE. Regression of myocardial and coronary vascular hypertrophy in hypertensive heart disease. J Cardiovasc Pharmacol 1988;12(Suppl. 4):S45-S54.
22. 22. Holmes B, Brogden RN, Heel RC, Speight TM, Avery GS. Guanabenz. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs 1983;26: 212-229.
23. 23. Guidelines Sub-committee. 1993 Guidelines for the management of mild hypertension: memorandum from a World Heath Organization/International Society of Hypertension meeting. J Hypertens 1993;11:905-918.
24. 24. Ohtomo N, Sumi A, Tanaka, Y, Tokiwano, K, Terachi S. A detailed study of power spectral density for Rossler system. J Phys Soc Jpn 1996;65:2811-2823.
25. 25. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Circulation 1977;55: 613-618.
26. 26. Nohta H, Mitsui A, Okura Y. Spectrofluorometric determination of catecholamines with 1,2-diphenylendiamine. Anal Chim Acta 1984;165:171-176.
27. 27. Kaplan JR, Pettersson K, Manuck SB, Olsson G. Role of sympathoadrenal medullary activation in the initiation and progression of atherosclerosis. Circulation 1991;846:VI23-VI32.
28. 28. Dibona GF. Sympathetic neural control of the kidney in hypertension. Hypertension 1992;191:128-135.
29. 29. Rosen MR, Danilo P Jr, Robinson RB, Shah A, Steinberg SF. Sympathetic neural and α-adrenergic modulation of arrhythmias. Ann N Y Acad Sci 1988;533:200-209.
30. 30. Levy D, Anderson KM, Savage DD, Balkus SA, Kannel WB, Castelli WP. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol 1987;60:560-565.
31. 31. Hartford M, Wilkstrand J, Wallentin I, Ljungman S, Berglund G. The relation between cardiac hypertrophy and hypertension. Acta Med Scand 1983;(Suppl 672):101-104.
32. 32. DiBona GF, Jones SY, Sawin LL. Renal sympathetic neural mechanisms as intermediate phenotype in spontaneously hypertensive rats. Hypertension 1996;27:626-630.
33. 33. Devereux RB. Do antihypertensive drugs differ in their ability to regress left ventricular hypertrophy? Circulation 1997;95:1983-1985.
34. 34. Cruickshank JM, Lewis J, Moore V, Dodd C. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens 1992;6:85-90.
35. 35. Gehr M, MacCarthy P, Goldberg M. Guanabenz. A centrally acting, natriuretic antihypertensive drug. Kidney Int 1986; 29:1203-1208.
36. 36. Regunathan S, Youngson C, Raasch W, Wang H, Reis DJ. Imidazoline receptors and agmatine in blood vessels: a novel system inhibiting vascular smooth muscle proliferation. J Pharmacol Exp Ther 1996;276:1272-1282.
37. 37. Dorman T, Clarkson K, Rosenfeld BA, Shanholtz C, Lipsett PA, Breslow MJ. Effects of clonidine on prolonged postoperative sympathetic response. Crit Care Med 1997;25:1147-1152.
38. 38. Stuhmeier KD, Mainzer B, Cierpka J, Sandmann W, Tarnow J. Small, oral dose of clonidine reduces the incidence of intraoperative myocardial ischemia in patients having vascular surgery. Anesthesiology 1996;85:706-712.